AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 446,500 shares, an increase of 38.4% from the February 13th total of 322,700 shares. Based on an average daily volume of 4,500 shares, the short-interest ratio is currently 99.2 days.
AstraZeneca Stock Down 0.6 %
AstraZeneca stock opened at $153.56 on Friday. The company has a fifty day simple moving average of $143.21 and a 200-day simple moving average of $144.37. AstraZeneca has a 12-month low of $120.64 and a 12-month high of $175.00.
AstraZeneca Increases Dividend
The company also recently disclosed a dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be given a dividend of $2.10 per share. This is a boost from AstraZeneca’s previous dividend of $1.00. The ex-dividend date of this dividend is Wednesday, February 19th. AstraZeneca’s payout ratio is 343.14%.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- What is diluted earnings per share (Diluted EPS)?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Plot Fibonacci Price Inflection Levels
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is Insider Trading? What You Can Learn from Insider Trading
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.